NEW YORK (GenomeWeb News) - Oxford Genome Sciences said last weekthat it is collaborating with Amgen to discover, develop, and commercialize therapeutic antibodies for cancer.
 
The companies will use Amgen’s XenoMouse technology to generate fully human anibodies, which will be raised against druggable targets that Oxford Genome Sciences has identified through its Oxford Genome Anatomy Project database of cancer proteins.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.